Symcel

21 articles about Symcel

• Symcel appoints two new board members to bolster R&D business growth and expansion into the clinical diagnostics market

  6/27/2018

  Symcel – has announced the appointment of two new highly experienced board members; Erik Walldén and Stefan Löfås.

• Symcel partners with Karolinska Institutet to validate calScreener™ in clinical antimicrobial susceptibility testing

  4/12/2018

  Symcel – the company behind the revolutionary cell-based assay tool for real-time cell metabolism measurements, calScreener™ – has partnered with the Karolinska Institutet in a Horizon 2020 funded project.

• Symcel Expands Staff for Clinical Market Growth and Horizon 2020 Funded Validation of Antimicrobial Susceptibility Testing

  2/8/2018

  Symcel is expanding to bring its patented technology to the clinical antimicrobial susceptibility testing markets.

• Symcel Secures €3.6 Million Horizon 2020 Phase II Grant for Clinical Validation of Customized Antimicrobial Susceptibility Testing Multi-Resistant Bacterial Sepsis Infections to be Validated Utilising Symcel's Sensitive Screening Technology

  11/21/2017

  The project runs over 28 months with a consortium of internationally recognized academic and clinical key opinion leaders from Karolinska Institutet, Hospital Universitario Ramón y Cajal, Careggi University Hospital, Rigshospitalet, IHE and Symcel.

• Jesper Ericsson Appointed New CEO Of Symcel

  9/5/2017

• Symcel: Calorimetry-Based 3D Phenotype Assays: A Necessity For Drug Discovery And Personalized Medicine

  6/19/2017

• Symcel: Phenotype Assays Needed For Antibiotic Resistance

  5/8/2017

• Symcel And Colzyx Partner To Test 25 Novel, First-In-Kind Collagen VI Derived Anti Microbial Peptides With calScreener

  12/20/2016

• Symcel, Tika Diagnostics And St. George's University Of London Form Partnership To Use Calscreener In Anti Microbial Susceptibililty Testing

  11/8/2016

• Symcel Secures Phase I Horizon 2020 Grant As The Company Plans For Full Scale Commercialisation Of calScreener – The World’s First Multi Channel Calorimetry System For Antimicrobial Susceptibility Testing

  7/27/2016

• Symcel Release: Initial €50,000 Phase 1 Grant Will Fund Full Feasibility Study

  7/18/2016

• Symcel Expands The Diverse Range Of Biological Applications Of Its Ground Breaking Assay Tool – The Calscreener Calorimeter

  6/23/2016

• Symcel Unveils Cellular Bio-Energetics Solutions That Enhance Phenotype Based Drug Discovery At The 2016 NovAliX Conference

  6/6/2016

• Symcel Secures SK 5.6 Million As Further Investment To Fund Marketing And Business Development Initiatives

  5/23/2016

• Symcel Enters The Realm Of Medical Diagnostics

  4/13/2016

• Symcel Tackles Antiobiotic Resistance With Calorimetry

  1/25/2016

• Symcel: Fighting Antibiotic Resistance With Calorimetry New Tools For Better Antimicrobial Drug Development

  12/10/2015

• Symcel: Overcoming Drug Development Cycle And Antibiotic Resistance Challenges

  10/1/2015

• Symcel Unveils International Installation Of Its Innovative Calscreener Technology Across Sweden, Switzerland, South Africa, Holland And Germany And South East Asia With Wide Ranging Applications

  6/2/2015

• Symcel’s Technology Opens New Research Avenues In Cancer Research, Diagnostics And The Development Of New Anti-Tumour Drugs

  3/17/2015